{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T13:14:44Z","timestamp":1718284484664},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T00:00:00Z","timestamp":1432771200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Digest Diseases"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the association of genetic variation in interleukin 28<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\"><jats:italic>IL\u201028B<\/jats:italic><\/jats:styled-content>) gene and viral factors with treatment outcome in chronic hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus (HCV)\u2010infected patients in Pakistan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection who received interferon plus ribavirin combination therapy were enrolled in the study. The viral loads were checked at the third and sixth month of treatment and 6 months after the completion of the treatment. Genotyping of single\u2010nucleotide polymorphism (<jats:styled-content style=\"fixed-case\">SNP)<\/jats:styled-content> rs12979860 of <jats:italic>IL\u201028B<\/jats:italic> gene was performed by the restriction fragment length polymorphism method and direct sequence analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 111 patients successfully completed antiviral therapy and the follow\u2010up period. Early virological response (<jats:styled-content style=\"fixed-case\">EVR<\/jats:styled-content>) and a sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) were achieved in 92 and 91 patients, respectively. Patients infected with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 3a had a higher <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rate compared with other <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotypes. A higher <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> allele frequency (81.9%) was observed in patients with <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> than those with non\u2010<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u2009=\u20090.00001). The odds ratio of achieving <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> was more than 10\u2010fold greater for the <jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content> genotype than the <jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">TT<\/jats:styled-content> genotypes of <jats:styled-content style=\"fixed-case\">SNP<\/jats:styled-content> rs12979860 (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> 10.351, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.925\u201355.653, <jats:italic>P<\/jats:italic>\u2009=\u20090.006). Other positive predictors observed for <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> were female gender and <jats:styled-content style=\"fixed-case\">EVR<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The <jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content> genotype of <jats:italic>IL\u201028B<\/jats:italic>\u2005<jats:styled-content style=\"fixed-case\">SNP<\/jats:styled-content> rs12979860 is an independent predictive factor for <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> in chronic HCV\u2010infected patients in <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>akistan.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1751-2980.12238","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T07:41:47Z","timestamp":1424763707000},"page":"293-298","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The genotype <scp>CC<\/scp> of <i><scp>IL\u201028B<\/scp><\/i>\u2005<scp>SNP<\/scp> rs12979860 is significantly associated with a sustained virological response in chronic HCV\u2010infected <scp>P<\/scp>akistani patients"],"prefix":"10.1111","volume":"16","author":[{"given":"Bushra","family":"Khubaib","sequence":"first","affiliation":[{"name":"National Centre of Excellence in Molecular Biology University of the Punjab  Lahore Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Saleem","sequence":"additional","affiliation":[{"name":"National Centre of Excellence in Molecular Biology University of the Punjab  Lahore Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Idrees","sequence":"additional","affiliation":[{"name":"National Centre of Excellence in Molecular Biology University of the Punjab  Lahore Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Afzal","sequence":"additional","affiliation":[{"name":"National Centre of Excellence in Molecular Biology University of the Punjab  Lahore Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Wasim","sequence":"additional","affiliation":[{"name":"Genome Center for Molecular\u2010based Diagnostics &amp; Research CL\u201025 Abdalian Cooperative Housing Society Lahore  Lahore Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2980.2008.00329.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2000.02108.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.12.014"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-234"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.370"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni873"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.447"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.449"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23624"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-9-5"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.03.001"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.35.1.201-207.1997"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.07.019"},{"key":"e_1_2_9_19_1","unstructured":"Online Encyclopedia for Genetic Epidemiology studies. Cited 7 March 2015. Available from URL:http:\/\/www.oege.org\/software\/hardy\u2010weinberg.html"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-8-69"},{"issue":"5","key":"e_1_2_9_21_1","first-page":"S3","article-title":"National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 \u2013 June 10\u201312, 2002","volume":"36","author":"National Institutes of Health","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.04904.x"},{"issue":"9138","key":"e_1_2_9_23_1","first-page":"1426","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard T.","year":"1998","journal-title":"International Hepatitis Interventional Therapy Group (IHIT)"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2011.05.018"}],"container-title":["Journal of Digestive Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1751-2980.12238","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1751-2980.12238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:45:12Z","timestamp":1696315512000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1751-2980.12238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/1751-2980.12238"],"URL":"https:\/\/doi.org\/10.1111\/1751-2980.12238","archive":["Portico"],"relation":{},"ISSN":["1751-2972","1751-2980"],"issn-type":[{"value":"1751-2972","type":"print"},{"value":"1751-2980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"2015-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}